JPH10501708A - 過分極した貴ガスを利用した磁気共鳴映像化 - Google Patents
過分極した貴ガスを利用した磁気共鳴映像化Info
- Publication number
- JPH10501708A JPH10501708A JP7526412A JP52641295A JPH10501708A JP H10501708 A JPH10501708 A JP H10501708A JP 7526412 A JP7526412 A JP 7526412A JP 52641295 A JP52641295 A JP 52641295A JP H10501708 A JPH10501708 A JP H10501708A
- Authority
- JP
- Japan
- Prior art keywords
- noble gas
- gas
- imaging
- noble
- magnetic resonance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052756 noble gas Inorganic materials 0.000 title claims abstract description 251
- 238000002595 magnetic resonance imaging Methods 0.000 title claims description 28
- 238000000034 method Methods 0.000 claims abstract description 125
- 238000003384 imaging method Methods 0.000 claims abstract description 86
- 238000005481 NMR spectroscopy Methods 0.000 claims abstract description 78
- 238000009826 distribution Methods 0.000 claims abstract description 45
- 241001465754 Metazoa Species 0.000 claims abstract description 38
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 32
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 32
- 238000012360 testing method Methods 0.000 claims abstract description 26
- FHNFHKCVQCLJFQ-YPZZEJLDSA-N xenon-129 atom Chemical compound [129Xe] FHNFHKCVQCLJFQ-YPZZEJLDSA-N 0.000 claims abstract description 25
- 239000000126 substance Substances 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 16
- SWQJXJOGLNCZEY-BJUDXGSMSA-N helium-3 atom Chemical compound [3He] SWQJXJOGLNCZEY-BJUDXGSMSA-N 0.000 claims abstract description 10
- 230000003444 anaesthetic effect Effects 0.000 claims abstract description 6
- 210000004789 organ system Anatomy 0.000 claims abstract 2
- 239000007789 gas Substances 0.000 claims description 57
- 150000002835 noble gases Chemical class 0.000 claims description 42
- 210000004072 lung Anatomy 0.000 claims description 41
- 230000002102 hyperpolarization Effects 0.000 claims description 33
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 claims description 17
- 210000001519 tissue Anatomy 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000007787 solid Substances 0.000 claims description 10
- 238000000338 in vitro Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 7
- IGLNJRXAVVLDKE-IGMARMGPSA-N rubidium-85 atom Chemical compound [85Rb] IGLNJRXAVVLDKE-IGMARMGPSA-N 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- IGLNJRXAVVLDKE-NJFSPNSNSA-N Rubidium-87 Chemical compound [87Rb] IGLNJRXAVVLDKE-NJFSPNSNSA-N 0.000 claims description 4
- 230000001588 bifunctional effect Effects 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 3
- GKAOGPIIYCISHV-OUBTZVSYSA-N neon-21 Chemical compound [21Ne] GKAOGPIIYCISHV-OUBTZVSYSA-N 0.000 claims description 3
- KEAYESYHFKHZAL-IGMARMGPSA-N sodium-23 atom Chemical compound [23Na] KEAYESYHFKHZAL-IGMARMGPSA-N 0.000 claims description 3
- DNNSSWSSYDEUBZ-BJUDXGSMSA-N krypton-83 Chemical compound [83Kr] DNNSSWSSYDEUBZ-BJUDXGSMSA-N 0.000 claims description 2
- 210000000944 nerve tissue Anatomy 0.000 claims description 2
- FHNFHKCVQCLJFQ-IGMARMGPSA-N xenon-131 Chemical compound [131Xe] FHNFHKCVQCLJFQ-IGMARMGPSA-N 0.000 claims description 2
- 239000012159 carrier gas Substances 0.000 claims 1
- -1 cesium-133 Chemical compound 0.000 claims 1
- 230000006870 function Effects 0.000 abstract description 18
- 238000001727 in vivo Methods 0.000 abstract description 5
- 230000001443 photoexcitation Effects 0.000 abstract description 4
- 239000002341 toxic gas Substances 0.000 abstract 1
- 229910052724 xenon Inorganic materials 0.000 description 60
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 59
- 230000005291 magnetic effect Effects 0.000 description 46
- 230000010287 polarization Effects 0.000 description 43
- 239000000523 sample Substances 0.000 description 38
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 22
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 21
- 229910052760 oxygen Inorganic materials 0.000 description 21
- 239000001301 oxygen Substances 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 210000004556 brain Anatomy 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 18
- 238000001228 spectrum Methods 0.000 description 18
- 239000011521 glass Substances 0.000 description 15
- 150000002632 lipids Chemical group 0.000 description 14
- 241000700159 Rattus Species 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 239000003193 general anesthetic agent Substances 0.000 description 9
- 229910052701 rubidium Inorganic materials 0.000 description 9
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 9
- 229940035674 anesthetics Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000005013 brain tissue Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000003568 synaptosome Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 241000283216 Phocidae Species 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000012935 Averaging Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 210000003739 neck Anatomy 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000005283 ground state Effects 0.000 description 4
- 230000005415 magnetization Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000004611 spectroscopical analysis Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 238000012800 visualization Methods 0.000 description 4
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- 108010029165 Metmyoglobin Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000002612 cardiopulmonary effect Effects 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 238000013480 data collection Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012454 non-polar solvent Substances 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 229910052594 sapphire Inorganic materials 0.000 description 2
- 239000010980 sapphire Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000004293 19F NMR spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241001385733 Aesculus indica Species 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001364569 Cofana spectra Species 0.000 description 1
- 241000270281 Coluber constrictor Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-IGMARMGPSA-N Fluorine-19 Chemical compound [19F] YCKRFDGAMUMZLT-IGMARMGPSA-N 0.000 description 1
- 241001364889 Helius Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108010061951 Methemoglobin Proteins 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- UJLFQHSVIUGIOA-UHFFFAOYSA-N [O].[Xe] Chemical compound [O].[Xe] UJLFQHSVIUGIOA-UHFFFAOYSA-N 0.000 description 1
- SERDEQHLHUMDDM-UHFFFAOYSA-N [O].[Xe].CCCCCCCCO Chemical compound [O].[Xe].CCCCCCCCO SERDEQHLHUMDDM-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000005281 excited state Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000003863 fast low-angle shot imaging Methods 0.000 description 1
- 238000002124 flame ionisation detection Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- OQZCSNDVOWYALR-UHFFFAOYSA-N flurochloridone Chemical compound FC(F)(F)C1=CC=CC(N2C(C(Cl)C(CCl)C2)=O)=C1 OQZCSNDVOWYALR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000005414 paramagnetic center Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012173 sealing wax Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
- G01R33/48—NMR imaging systems
- G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
- G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
- G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1815—Suspensions, emulsions, colloids, dispersions compo-inhalant, e.g. breath tests
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
- G01R33/00—Arrangements or instruments for measuring magnetic variables
- G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
- G01R33/28—Details of apparatus provided for in groups G01R33/44 - G01R33/64
- G01R33/282—Means specially adapted for hyperpolarisation or for hyperpolarised contrast agents, e.g. for the generation of hyperpolarised gases using optical pumping cells, for storing hyperpolarised contrast agents or for the determination of the polarisation of a hyperpolarised contrast agent
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Veterinary Medicine (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Signal Processing (AREA)
- High Energy & Nuclear Physics (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Magnetic Variables (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.核磁気共鳴(NMR)映像化方法において a)NMRにより貴ガスの空間分布を検出し、さらに b)前記貴ガスの前記空間分布の表示を生成する、 ステップから構成されることを特徴とする核磁気共鳴映像化方法。 2.前記貴ガスがヘリウム−3、ネオン−21、クリプトン−83、キセノン− 129、キセノン−131、およびそれらの混合物からなる群から選択されるこ とを特徴とする請求の範囲第1項に記載の方法。 3.前記貴ガスの少なくとも一つのガスに、キセノン−129が含まれることを 特徴とする請求の範囲第2項に記載の方法。 4.前記貴ガスに、ヘリウム−3が含まれることを特徴とする請求の範囲第2項 に記載の方法。 5.前記貴ガスにキセノン−129とヘリウム−3が含まれることを特徴とする 請求の範囲第2項に記載の方法。 6.前記検出するステップの前に前記貴ガスを過分極するステップを更に含むこ とを特徴とする請求の範囲第1項に記載の方法。 7.前記過分極するステップが、アルカリ金属とのスピン交換を介して前記貴ガ スを過分極することからなることを特徴とする請求の範囲第6項に記載の方法。 8.前記過分極するステップが、準安定交換を介して前記貴ガスを過分極するこ とからなることを特徴とする請求の範囲第6項に記載の方法。 9.前記アルカリ金属が、ナトリウム−23、カリウム−39、セシウム−133 、ルビジウム−85、ルビジウム−87からなる群から選択されていることを特 徴とする請求の範囲第7項に記載の方法。 10.前記アルカリ金属が、ルビジウム−85およびルビジウム−87からなる群 から選択されることを特徴とする請求の範囲第9項に記載の方法。 11.前記検出ステップが、少なくとも1つの物理次元に沿って前記貴ガスの前記 空間分布を検出すること含むことを特徴とする請求の範囲第1項に記載の方法。 12.前記検出ステップが、2つの物理次元に沿って前記貴ガスの前記空間分布を 検出することを含むことを特徴とする請求の範囲第11項に記載の方法。 13.前記検出ステップが、3つの物理次元に沿って前記貴ガスの前記空間分布を 検出することからなることを特徴とする請求の範囲第11項に記載の方法。 14.前記表示に、視覚表示が含まれることを特徴とする請求の範囲第1項に記載 の方法。 15.前記検出ステップが前記生成ステップより先行して行われることを特徴とす る請求の範囲第1項に記載の方法。 16.前記検出ステップと前記生成ステップがほぼ同時に行われることを特徴とす る請求の範囲第1項に記載の方法。 17.前記生成するステップに、NMRパラメータデータから前記表示を生成する ことが含まれることを特徴とする請求の範囲第1項に記載の方法。 18.前記NMRパラメータデータに、化学シフト、T1緩和、T2緩和、およびT1 ρ緩和からなる群から選ばれた少なくとも一つの物理的に測定できるNMRパ ラメータからコンピューターにより誘導されたデータが含まれることを特徴とす る請求の範囲第17項に記載の方法。 19.前記少なくとも一つの貴ガスが、少なくとも一つの物理相中に分布している ことを特徴とする請求の範囲第1項に記載の方法。 20.前記少なくとも一つの貴ガスが、気相中に分布していることを特徴とする請 求の範囲第19項に記載の方法。 21.前記少なくとも一つの貴ガスが、液体中に分布していることを特徴とする請 求の範囲第19項に記載の方法。 22.前記少なくとも一つの貴ガスが、固体中に分布していることを特徴とする請 求の範囲第19項に記載の方法。 23.前記少なくとも一つの貴ガスが、固体表面に分布していることを特徴とする 請求の範囲第22項に記載の方法。 24.前記少なくとも一つの貴ガスが、少なくとも2つの物理相中に分布している ことを特徴とする請求の範囲第19項に記載の方法。 25.前記少なくとも一つの貴ガスが、生体外化学系に分布していることを特徴と する請求の範囲第1項に記載の方法。 26.前記少なくとも一つの貴ガスが、生体外生物系に分布していることを特徴と する請求の範囲第1項に記載の方法。 27.前記貴ガスが、ヒト被験者または被験動物中に分布していることを特徴とす る請求の範囲第1項に記載の方法。 28.前記貴ガスが、前記ヒト被験者または被験動物の臓器系または身体系に分布 していることを特徴とする請求の範囲第27項に記載の方法。 29.前記貴ガスが、前記ヒト被験者または被験動物の肺組織に分布していること を特徴とする請求の範囲第28項に記載の方法。 30.前記貴ガスが、前記ヒト被験者または被験動物の神経組織に分布しているこ とを特徴とする請求の範囲第28項に記載の方法。 31.前記貴ガスが、前記ヒト被験者または被験動物の能組織に分布していること を特徴とする請求の範囲第30項に記載の方法。 32.前記貴ガスが、前記ヒト被験者または被験動物の解剖腔に分布していること を特徴とする請求の範囲第27項に記載の方法。 33.前記解剖腔に、肺腔が含まれることを特徴とする請求の範囲第32項に記載 の方法。 34.前記解剖腔に、胃腸管腔が含まれることを特徴とする請求の範囲第32項に 記載の方法。 35.前記貴ガスをヒト被験者または被験動物に投与することを更に含むことを特 徴とする請求の範囲第1項に記載の方法。 36.前記貴ガスを投与するステップに、前記貴ガスをガス状にて投与することが 含まれることを特徴とする請求の範囲第35項に記載の方法。 37.前記貴ガスを投与するステップに、前記貴ガスを前記ヒト被験者または被験 動物に受動的または能動的吸入により投与することが含まれることを特徴とする 請求の範囲第36項に記載の方法。 38.前記貴ガスを投与するステップに、前記貴ガスを液体組成物として前記ヒト 被験者または被験動物に投与することが含まれることを特徴とする請求の範囲第 35項に記載の方法。 39.前記貴ガスを投与するステップに、前記貴ガスを非経口注射することが含ま れることを特徴とする請求の範囲第38項に記載の方法。 40.前記貴ガスを投与するステップに、前記貴ガスを静注することが含まれるこ とを特徴とする請求の範囲第39項に記載の方法。 41.前記貴ガスを投与するステップに、血液に前記貴ガスを導入し、更に前記ヒ ト被験者または被験動物に前記貴ガス含有血液を静注することが含まれることを 特徴とする請求の範囲第40項に記載の方法。 42.前記表示が、前記貴ガス空間分布の少なくとも1つの空間次元を表すことを 特徴とする請求の範囲第1項に記載の方法。 43.前記表示が、前記貴ガス空間分布の2つの空間次元を表すことを特徴とする 請求の範囲第1項に記載の方法。 44.前記表示が、前記貴ガス空間分布の3つの空間次元を表すことを特徴とする 請求の範囲第1項に記載の方法。 45.前記表示が、さらに前記貴ガス空間分布の少なくとも1つの空間次元を時間 の関数として表すことを特徴とする請求の範囲第42項に記載の方法。 46.核磁気共鳴映像化装置において、 a)過分極貴ガスの空間分布をNMRにより映像化する手段、および b)前記映像化手段により映像化される試料に映像化可能量の前記過分極貴 ガスを供給する手段、 から構成されていることを特徴とする核磁気共鳴映像化装置。 47.前記供給する手段に、過分極貴ガスを発生するために前記貴ガスを過分極す る手段が含まれることを特徴とする請求の範囲第46項に記載の装置。 48.前記過分極する手段に、アルカリ金属とのスピン交換により前記貴ガスを過 分極する手段が含まれることを特徴とする請求の範囲第47項に記載の装置。 49.前記過分極する手段に、準安定交換により前記貴ガスを過分極する手段が含 まれることを特徴とする請求の範囲第47項に記載の装置。 50.前記過分極する手段に、前記過分極貴ガスを貯蔵する手段が更に含まれるこ とを特徴とする請求の範囲第47項に記載の装置。 51.生体内で麻酔学的機能並びに磁気共鳴映像化機能が同時に有効な医療上使用 できる2機能性ガスを含有することを特徴とする医療用組成物。 52.前記2機能性ガスが、少なくとも一つの過分極貴ガスを含有することを特徴 とする請求の範囲第51項に記載の医療用組成物。 53.前記2機能性ガスが、さらに医療上使用できるキャリアガスを含有すること を特徴とする請求の範囲第51項に記載の医療用組成物。 54.ヒト被験者または被験動物の核磁気共鳴(NMR)映像化を行う方法におい て、 a)前記ヒト被験者または被験動物に映像化可能量の過分極貴ガスを投与し 、 b)核磁気共鳴映像化分光計により過分極貴ガスからラジオ波シグナルを生 成し、 c)過分極貴ガスの核磁気共鳴から導かれたラジオ波シグナルを検出し、 d)過分極貴ガスの空間分布の関数として一組のNMRパラメータデータを 提供するために前記ラジオ波シグナルを処理し、さらに e)過分極貴ガスの空間分布の少なくとも1つの空間次元に対応する表示を 導くために一組のNMRパラメータデータをさらに処理する、 各ステップから構成されていることを特徴とするヒト被験者または被験動物の 核磁気共鳴(NMR)映像化を行う方法。 55.前記投与するステップが、前記ヒト被験者または被験動物へガス組成物を投 与することを含むことを特徴とする請求の範囲第54項に記載の方法。 56.前記投与するステップが、前記ヒト被験者または被験動物による前記ガス組 成物の受動的または能動的吸入を含むことを特徴とする請求の範囲第55項に記 載の方法。 57.前記投与ステップが、少なくとも一つのボーラスとして前記貴ガスの投与を さらに含むことを特徴とする請求の範囲第55項に記載の方法。 58.前記投与ステップが、生成および検出ステップの間に前記貴ガスの連続投与 を含むことを特徴とする請求の範囲第55項に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/225,243 US5545396A (en) | 1994-04-08 | 1994-04-08 | Magnetic resonance imaging using hyperpolarized noble gases |
| US08/225,243 | 1994-04-08 | ||
| PCT/US1995/004175 WO1995027438A1 (en) | 1994-04-08 | 1995-04-04 | Magnetic resonance imaging using hyperpolarized noble gases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10501708A true JPH10501708A (ja) | 1998-02-17 |
| JP3645569B2 JP3645569B2 (ja) | 2005-05-11 |
Family
ID=22844121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP52641295A Expired - Fee Related JP3645569B2 (ja) | 1994-04-08 | 1995-04-04 | 過分極した貴ガスを利用した磁気共鳴映像化 |
Country Status (8)
| Country | Link |
|---|---|
| US (5) | US5545396A (ja) |
| EP (2) | EP0754009B1 (ja) |
| JP (1) | JP3645569B2 (ja) |
| AT (1) | ATE449615T1 (ja) |
| AU (1) | AU709515B2 (ja) |
| CA (1) | CA2183740C (ja) |
| DE (1) | DE69536022D1 (ja) |
| WO (1) | WO1995027438A1 (ja) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002511329A (ja) * | 1998-04-09 | 2002-04-16 | メディ−フィジックス・インコーポレイテッド | 肺からの酸素吸収における領域変化のmri検出のための過分極ガスの使用 |
| JP2002534683A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | Nmr分光法 |
| JP2002534687A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | 過分極を使用したnmr分光学アッセイ |
| JP2018512384A (ja) * | 2015-02-20 | 2018-05-17 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 溶解ガス発生流体を有するコントラスト造影剤 |
Families Citing this family (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6088613A (en) | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US6551576B1 (en) | 1989-12-22 | 2003-04-22 | Bristol-Myers Squibb Medical Imaging, Inc. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
| US6001335A (en) | 1989-12-22 | 1999-12-14 | Imarx Pharmaceutical Corp. | Contrasting agents for ultrasonic imaging and methods for preparing the same |
| US5469854A (en) | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
| US20020150539A1 (en) | 1989-12-22 | 2002-10-17 | Unger Evan C. | Ultrasound imaging and treatment |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| US5776429A (en) | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
| US5922304A (en) | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US6146657A (en) | 1989-12-22 | 2000-11-14 | Imarx Pharmaceutical Corp. | Gas-filled lipid spheres for use in diagnostic and therapeutic applications |
| US5874062A (en) | 1991-04-05 | 1999-02-23 | Imarx Pharmaceutical Corp. | Methods of computed tomography using perfluorocarbon gaseous filled microspheres as contrast agents |
| US5205290A (en) | 1991-04-05 | 1993-04-27 | Unger Evan C | Low density microspheres and their use as contrast agents for computed tomography |
| US6280383B1 (en) | 1993-03-01 | 2001-08-28 | Fonar Corporation | Magnetic resonance imaging |
| US7083572B2 (en) | 1993-11-30 | 2006-08-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Therapeutic delivery systems |
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| US6743779B1 (en) | 1994-11-29 | 2004-06-01 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| US5830430A (en) | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
| US5997898A (en) | 1995-06-06 | 1999-12-07 | Imarx Pharmaceutical Corp. | Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery |
| US6033645A (en) | 1996-06-19 | 2000-03-07 | Unger; Evan C. | Methods for diagnostic imaging by regulating the administration rate of a contrast agent |
| US6231834B1 (en) | 1995-06-07 | 2001-05-15 | Imarx Pharmaceutical Corp. | Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same |
| US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
| US5617860A (en) * | 1995-06-07 | 1997-04-08 | Smithsonian Astrophysical Observatory | Method and system for producing polarized 129 Xe gas |
| US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
| US5626137A (en) * | 1995-10-02 | 1997-05-06 | General Electric Company | Apparatus and methods for magnetic resonance (MR) angiography using fluids polarized at low temperatures |
| FR2744932B1 (fr) * | 1996-02-16 | 1998-04-30 | Centre Nat Rech Scient | Installation et procede pour la production d'helium-3 polarise en phase vapeur, en particulier pour l'imagerie par rmn |
| US5809801A (en) * | 1996-03-29 | 1998-09-22 | The Trustees Of Princeton University | Cryogenic accumulator for spin-polarized xenon-129 |
| FI982069A7 (fi) * | 1996-03-29 | 1998-11-10 | Lawrence Berkeley Nat Laboratory | NMR:n ja MRI:n tehostaminen hyperpolaroitujen jalokaasujen läsnä olles sa |
| US5642625A (en) * | 1996-03-29 | 1997-07-01 | The Trustees Of Princeton University | High volume hyperpolarizer for spin-polarized noble gas |
| US8765099B2 (en) * | 1996-04-08 | 2014-07-01 | Koninklijke Philips N.V. | Magnetic resonance imaging hyperpolarization of liquids or solids by light with orbital angular momentum |
| WO1997040679A1 (en) | 1996-05-01 | 1997-11-06 | Imarx Pharmaceutical Corp. | Methods for delivering compounds into a cell |
| DE19619471C1 (de) * | 1996-05-14 | 1997-10-16 | Siemens Ag | Kernspintomographiegerät mit Vorpolarisation |
| US6414139B1 (en) | 1996-09-03 | 2002-07-02 | Imarx Therapeutics, Inc. | Silicon amphiphilic compounds and the use thereof |
| ES2289188T3 (es) | 1996-09-11 | 2008-02-01 | Bristol-Myers Squibb Medical Imaging, Inc. | Procedimiento para la obtencion de imagenes para el diagnostico usando un agente de contraste y un vasodilatador. |
| US5846517A (en) | 1996-09-11 | 1998-12-08 | Imarx Pharmaceutical Corp. | Methods for diagnostic imaging using a renal contrast agent and a vasodilator |
| EP0951650B1 (en) | 1997-01-08 | 2003-12-10 | Amersham Health AS | Method of magnetic resonance imaging |
| NZ337535A (en) * | 1997-03-10 | 2000-06-23 | Michael Georgieff | A device for controlled anaesthesia, analgesia and/or sedation using an emulsion containing inert gas |
| DE19709704C2 (de) * | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US6537246B1 (en) | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US7452551B1 (en) | 2000-10-30 | 2008-11-18 | Imarx Therapeutics, Inc. | Targeted compositions for diagnostic and therapeutic use |
| US6416740B1 (en) | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| ATE252916T1 (de) * | 1997-08-12 | 2003-11-15 | Bracco Research Sa | Verabreichbare formulierugen und ihre anwendung in mri |
| ATE366134T1 (de) | 1997-08-18 | 2007-07-15 | Univ Princeton | Spin-polarisation eines edelgases über spinaustausch mit optisch gepumpten alkalimetallen |
| US6112108A (en) * | 1997-09-12 | 2000-08-29 | Ramot University For Applied Research & Industrial Development Ltd. | Method for diagnosing malignancy in pelvic tumors |
| US6548047B1 (en) | 1997-09-15 | 2003-04-15 | Bristol-Myers Squibb Medical Imaging, Inc. | Thermal preactivation of gaseous precursor filled compositions |
| FR2768568B1 (fr) | 1997-09-17 | 2000-02-25 | Centre Nat Rech Scient | Procede et equipement pour la preparation d'un gaz d'helium hyperpolarise a forte pression, application dudit procede |
| EP1030594A1 (en) | 1997-11-14 | 2000-08-30 | Norbert Weiler | Apparatus for fluid administration |
| HU222711B1 (hu) * | 1997-12-12 | 2003-09-29 | Medi-Physics, Inc, | Polarizált gáz akkumulátor és fżtżköpeny, eljárás polarizált gáz összegyżjtésére és felengedésére, valamint polarizált gáztermék |
| AU2003203796B2 (en) * | 1997-12-12 | 2006-10-12 | Medi-Physics, Inc. | Polarized gas accumulators and heating jackets and associated gas collection and thaw methods and polarized gas products |
| EP1279912B1 (en) * | 1997-12-12 | 2005-03-02 | Medi-Physics, Inc. | Methods of collecting and thawing polarised gases, associated accumulators and heating jackets |
| US6079213A (en) * | 1997-12-12 | 2000-06-27 | Magnetic Imaging Technologies Incorporated | Methods of collecting, thawing, and extending the useful life of polarized gases and associated accumulators and heating jackets |
| EP1051602B1 (en) | 1997-12-12 | 2003-04-23 | Medi-Physics, Inc. | Process to solidify and thaw a polarized gas comprising xenon |
| US6123923A (en) | 1997-12-18 | 2000-09-26 | Imarx Pharmaceutical Corp. | Optoacoustic contrast agents and methods for their use |
| US6278893B1 (en) | 1998-01-05 | 2001-08-21 | Nycomed Imaging As | Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| US6185444B1 (en) * | 1998-03-13 | 2001-02-06 | Skelscan, Inc. | Solid-state magnetic resonance imaging |
| EP1286171A3 (en) * | 1998-03-18 | 2003-05-28 | Medi-Physics, Inc. | MR evaluation of vascular perfusion by means of hyperpolarized 129Xe |
| JP2002507438A (ja) | 1998-03-18 | 2002-03-12 | メディ−フィジックス・インコーポレイテッド | 溶解化した極性化129Xeを用いる肺および心臓脈管構造の映像化および血流を上昇するMR方法 |
| WO1999053332A1 (en) * | 1998-04-09 | 1999-10-21 | Medi-Physics, Inc. | Use of a hyperpolarized gas for mri detection of regional variations in oxygen uptake from the lungs |
| US6370415B1 (en) | 1998-04-10 | 2002-04-09 | Medi-Physics Inc. | Magnetic resonance imaging method |
| AU3386799A (en) * | 1998-04-13 | 1999-11-01 | Duke University | (in vivo) magnetic resonance vascular imaging using laser-polarized gas microbubbles |
| ATE523776T1 (de) | 1998-06-17 | 2011-09-15 | Medi Physics Inc | Elastische behälter für hyperpolarisierte gase |
| US6128918A (en) * | 1998-07-30 | 2000-10-10 | Medi-Physics, Inc. | Containers for hyperpolarized gases and associated methods |
| BR9911346A (pt) * | 1998-06-17 | 2001-03-13 | Medi Physics Inc | Dispositivo de transporte de gás hiperpolarizado e método de transporte associado |
| US6423387B1 (en) | 1998-06-17 | 2002-07-23 | Medi-Physics, Inc. | Resilient containers for hyperpolarized gases and associated methods |
| DE19833014A1 (de) * | 1998-07-23 | 2000-01-27 | Messer Griesheim Gmbh | Edelgashaltige Injektionsanästhesiemittel |
| US6023162A (en) * | 1998-07-23 | 2000-02-08 | Duke University | Three-dimensional morphology by magnetic resonance imaging |
| US6159444A (en) * | 1998-09-11 | 2000-12-12 | The Regents Of The University Of California | NMR/MRI with hyperpolarized gas and high Tc SQUID |
| US6286319B1 (en) | 1998-09-30 | 2001-09-11 | Medi-Physics, Inc. | Meted hyperpolarized noble gas dispensing methods and associated devices |
| US6237363B1 (en) | 1998-09-30 | 2001-05-29 | Medi-Physics, Inc. | Hyperpolarized noble gas extraction methods masking methods and associated transport containers |
| US6523356B2 (en) | 1998-09-30 | 2003-02-25 | Medi-Physics, Inc. | Meted hyperpolarized noble gas dispensing methods and associated devices |
| US6125654A (en) * | 1998-10-16 | 2000-10-03 | Syracuse University | Bulk production and usage of hyperpolarized 129 Xenon |
| US6284222B1 (en) | 1998-11-03 | 2001-09-04 | Medi--Physics, Inc. | Hyperpolarized helium-3 microbubble gas entrapment methods |
| FR2787835B1 (fr) | 1998-12-23 | 2004-09-24 | Centre Nat Rech Scient | Compresseurs peristaltiques adaptes a la compression non relaxante de gaz polarise |
| EP1155339A1 (en) | 1999-02-23 | 2001-11-21 | Medi-Physics, Inc. | Portable system for monitoring the polarization level of a hyperpolarized gas during transport |
| US6408849B1 (en) * | 1999-06-18 | 2002-06-25 | Aeronex, Inc. | Recovery and purification of gases used in medical processes |
| US6295834B1 (en) | 1999-06-30 | 2001-10-02 | Medi-Physics, Inc. | NMR polarization monitoring coils, hyperpolarizers with same, and methods for determining the polarization level of accumulated hyperpolarized noble gases during production |
| WO2001005409A1 (de) * | 1999-07-19 | 2001-01-25 | Michael Georgieff | Neues spinal- und epiduralanästhetikum |
| US6611540B1 (en) | 1999-07-29 | 2003-08-26 | Otward Maria Mueller | Diode-laser system for hyperpolarized He-3 and Xe-129 gas generation and other applications |
| US6338836B1 (en) | 1999-09-28 | 2002-01-15 | Siemens Aktiengesellschaft | Asthma analysis method employing hyperpolarized gas and magnetic resonance imaging |
| DE10000675C2 (de) | 2000-01-11 | 2001-11-15 | Otten Ernst Wilhelm | Lineardurchführung, Vorrichtung und Verfahren zur hochproduktiven Erzeugung von hoch kernspinpolarisiertem Helium-3 Gas |
| US6630126B2 (en) * | 2000-03-13 | 2003-10-07 | Medi-Physics, Inc. | Diagnostic procedures using direct injection of gaseous hyperpolarized 129Xe and associated systems and products |
| US6845262B2 (en) | 2000-03-29 | 2005-01-18 | The Brigham And Women's Hospital, Inc. | Low-field MRI |
| WO2001074247A2 (en) * | 2000-04-03 | 2001-10-11 | Iep Pharmaceutical Devices Inc. | Method for measuring changes in the airways of humans and other mammals |
| US6775568B2 (en) * | 2000-04-12 | 2004-08-10 | University Of Virginia Patent Foundation | Exchange-based NMR imaging and spectroscopy of hyperpolarized xenon-129 |
| GB0014463D0 (en) * | 2000-06-14 | 2000-08-09 | Nycomed Amersham Plc | NMR Method |
| EP1303646B1 (en) * | 2000-07-12 | 2008-04-16 | The University of New Hampshire | Method for polarizing nuclear species |
| US20030165431A1 (en) * | 2000-07-13 | 2003-09-04 | The Regents Of The University Of California | Method for detecting macromolecular conformational change and binding information |
| US6652833B2 (en) * | 2000-07-13 | 2003-11-25 | The Regents Of The University Of California | Functionalized active-nucleus complex sensor |
| CA2414610A1 (en) * | 2000-07-13 | 2002-01-24 | Medi-Physics, Inc. | Diagnostic procedures using 129xe spectroscopy characteristic chemical shift to detect pathology in vivo |
| US7061237B2 (en) * | 2000-07-13 | 2006-06-13 | The Regents Of The University Of California | Remote NMR/MRI detection of laser polarized gases |
| US6714808B2 (en) | 2000-10-03 | 2004-03-30 | University Of Arkansas | Method for detecting and excising nonpalpable lesions |
| US7174200B2 (en) * | 2001-04-13 | 2007-02-06 | University Of Virginia Patent Foundation | Optimized high-speed magnetic resonance imaging method and system using hyperpolarized noble gases |
| US7850152B2 (en) | 2001-04-24 | 2010-12-14 | Medi Physics, Inc. | Methods and devices for moisturizing hyperpolarized noble gases and associated moisturized pharmaceutical grade inhalable hyperpolarized gas products |
| US6626027B1 (en) | 2001-06-12 | 2003-09-30 | Intertech Development Company | Method and apparatus for detecting a gas leak using nuclear magnetic resonance |
| EP1436637A1 (en) * | 2001-09-20 | 2004-07-14 | Medi-Physics, Inc. | Methods for in vivo evaluation of physiological conditions and/or organ or system function including methods to evaluate cardiopulmonary disorders such as chronic heart failure using polarized 129 xe |
| US7179450B2 (en) * | 2001-09-20 | 2007-02-20 | Medi-Physics, Inc. | Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe |
| US20030212320A1 (en) * | 2001-10-01 | 2003-11-13 | Michael Wilk | Coordinate registration system for dual modality imaging systems |
| CA2463739C (en) * | 2001-10-22 | 2013-10-08 | Medi-Physics Inc. | Automated modular hyperpolarizers |
| AU2002348040A1 (en) * | 2001-10-22 | 2003-05-06 | Medi-Physics, Inc. | Optical pumping modules, polarized gas blending and dispensing systems, and automated polarized gas distribution systems |
| AU2003237848A1 (en) * | 2002-05-15 | 2003-12-02 | University Of Virginia Patent Foundation | Method and system for rapid magnetic resonance imaging of gases with reduced diffusion-induced signal loss |
| AU2003269207A1 (en) * | 2002-05-16 | 2003-12-02 | Medi-Physics, Inc | Methods and systems for determining polarization of a gas based on electron paramagnetic resonance |
| AU2003248529A1 (en) * | 2002-05-17 | 2003-12-02 | Medi-Physics, Inc | Methods, systems, circuits, and computer program products for determining polarization of a gas |
| EP1534990B1 (en) * | 2002-07-23 | 2006-10-25 | Medi-Physics, Inc. | Automated dynamic pressure-responsive hyperpolarized gas dispensing systems, and associated methods and computer program products |
| AU2003259846A1 (en) * | 2002-08-16 | 2004-03-03 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
| US20040082851A1 (en) * | 2002-10-29 | 2004-04-29 | Mehmet Bilgen | Tunable electromagnetic device and method of use |
| US6867591B2 (en) * | 2002-12-20 | 2005-03-15 | Medi-Physics, Inc. | NMR transfer standard |
| JP3998243B2 (ja) * | 2003-01-10 | 2007-10-24 | 東横化学株式会社 | 核スピン偏極キセノンガスの製造方法及び製造装置 |
| US20040184963A1 (en) | 2003-01-17 | 2004-09-23 | Cella Patrick A. | Recirculating hyperpolarized gas cells and associated methods of producing optically pumped hyperpolarized gas |
| US7275540B2 (en) * | 2003-04-22 | 2007-10-02 | Medi-Physics, Inc. | MRI/NMR-compatible, tidal volume control and measurement systems, methods, and devices for respiratory and hyperpolarized gas delivery |
| US7805176B2 (en) * | 2004-03-10 | 2010-09-28 | University Of Virginia Patent Foundation | Exchange-weighted xenon-129 nuclear magnetic resonance system and related method |
| US20070197903A1 (en) * | 2004-03-10 | 2007-08-23 | Mugler John P Iii | System and method for improved detection and assessment of changes in lung-tissue structure |
| US7281393B2 (en) * | 2004-04-21 | 2007-10-16 | University Of New Hampshire | Method and apparatus for accumulating hyperpolarized xenon |
| FI20045381A0 (fi) * | 2004-10-12 | 2004-10-12 | Oulun Yliopisto | Huokosominaisuuden määritysmenetelmä, näyteyksikön valmistusmenetelmä ja näyteyksikkö |
| US7991449B2 (en) * | 2005-04-26 | 2011-08-02 | Mayo Foundation For Medical Education And Research | Imaging elastic properties of the lung with magnetic resonance elastography |
| JP4696262B2 (ja) * | 2005-05-18 | 2011-06-08 | 独立行政法人産業技術総合研究所 | 超偏極希ガス製造装置及び超偏極希ガスを用いた核磁気共鳴分光装置並びに磁気共鳴イメージング装置 |
| DE102005026604A1 (de) * | 2005-06-09 | 2006-12-14 | Membrana Gmbh | Verfahren zum Lösen von Gasen mit kurzlebigen physikalischen Eigenschaften in einer Flüssigkeit |
| US20070190663A1 (en) * | 2005-08-12 | 2007-08-16 | Lee Ray F | System and method for using polarized or hyperpolarized contrast agent to perform parallel magnetic resonance imaging of a sample |
| EP1926425B1 (en) | 2005-09-13 | 2015-08-19 | Philips Intellectual Property & Standards GmbH | Multiple contrast agent injection for imaging |
| WO2007038626A2 (en) * | 2005-09-28 | 2007-04-05 | President And Fellows Of Harvard College | Hyperpolarized solid materials with long spin relaxation times for use as imaging agents in magnetic resonance imaging |
| WO2007070466A2 (en) * | 2005-12-10 | 2007-06-21 | The President And Fellows Of Harvard College | In situ hyperpolarization of imaging agents |
| EP1984757A4 (en) * | 2006-01-11 | 2009-11-04 | Harvard College | EX-VIVO HYPERPOLARIZATION OF ILLUSTRATORS |
| WO2007087313A2 (en) * | 2006-01-25 | 2007-08-02 | The Trustees Of Columbia University In The City Of New York | Systems and methods for determining metabolic rate using temperature sensitive magnetic resonance imaging |
| US20090227859A1 (en) * | 2006-01-25 | 2009-09-10 | John Pile-Spellman | Systems and methods for determining a cardiovascular parameter using temperature sensitive magnetic resonance imaging |
| US20140218029A1 (en) * | 2006-02-21 | 2014-08-07 | Millikelvin Technologies Llc | Techniques, systems and machine readable programs for magnetic resonance |
| US9207298B2 (en) | 2011-03-23 | 2015-12-08 | Millikelvin Technologies Llc | Techniques, systems and machine readable programs for magnetic resonance |
| EP1986702A4 (en) * | 2006-02-21 | 2012-12-12 | Avrum Belzer | HYPERPOLARIZATION PROCEDURES, SYSTEMS AND COMPOSITIONS |
| US8703102B2 (en) * | 2008-04-04 | 2014-04-22 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| US7576538B2 (en) * | 2006-03-14 | 2009-08-18 | Thomas Meersmann | Nuclear electric quadrupolar properties of hyperpolarized gases to probe surfaces and interfaces |
| WO2007123799A2 (en) * | 2006-04-03 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Assessing subject's reactivity to psychological stress using fmri |
| US7282910B1 (en) * | 2006-04-19 | 2007-10-16 | Northrop Grumman Corporation | Nuclear magnetic resonance gyroscope |
| US7714581B2 (en) | 2006-04-19 | 2010-05-11 | Wisconsin Alumni Research Foundation | RF coil assembly for magnetic resonance imaging and spectroscopy systems |
| US7885702B2 (en) * | 2006-04-19 | 2011-02-08 | Wisconsin Alumni Research Foundation | Segmentation of the airway tree using hyperpolarized noble gases and diffusion weighted magnetic resonance imaging |
| EP2067052B1 (en) * | 2006-09-20 | 2016-05-11 | University Of New Hampshire | Thermal management technology for polarizing xenon |
| US8405022B2 (en) | 2006-09-20 | 2013-03-26 | University Of New Hampshire | Thermal management technology for polarizing xenon |
| CA3065182C (en) * | 2006-10-03 | 2022-05-17 | Duke University | Systems and methods for assessing pulmonary gas transfer using hyperpolarized 129xe mri |
| US7508212B2 (en) | 2007-03-22 | 2009-03-24 | Wisconsin Alumni Research Foundation | RF coil assembly and method for practicing magnetization transfer on magnetic resonance imaging and spectroscopy systems |
| WO2009143368A2 (en) * | 2008-05-23 | 2009-11-26 | University Of Utah | Non-cryogenic storage cell for hyperpolarized 129xe |
| US20100092390A1 (en) * | 2008-10-09 | 2010-04-15 | President And Fellows Of Harvard College | Methods for Making Particles Having Long Spin-Lattice Relaxation Times |
| CN102460136A (zh) * | 2009-06-19 | 2012-05-16 | 皇家飞利浦电子股份有限公司 | 与利用具有轨道角动量的光子的超极化装置组合的mri温度测定 |
| RU2526895C2 (ru) * | 2009-06-19 | 2014-08-27 | Конинклейке Филипс Электроникс Н.В. | Мрт с гиперполяризационным устройством, использующим фотоны с орбитальным угловым моментом |
| JP3180510U (ja) * | 2009-08-26 | 2012-12-27 | アスペクト マグネット テクノロジーズ リミテッド | 不分極ガスを過分極化するシステム及び過分極化ガス・イメージングシステム |
| CA2772190A1 (en) * | 2009-08-31 | 2011-03-03 | Millikelvin Technologies Llc | Systems and methods for producing hyperpolarized materials and mixtures thereof |
| BR112012020235A2 (pt) * | 2010-02-16 | 2017-11-07 | Koninl Philips Electronics Nv | "dispensador para a produção de um agente de contraste hiperpolarizado e sistema de exame de ressonância magnética" |
| US8598881B2 (en) | 2011-01-11 | 2013-12-03 | General Electric Company | Magnetic resonance imaging system with thermal reservoir and method for cooling |
| US9714995B2 (en) | 2011-03-23 | 2017-07-25 | Millikelvin Technologies Llc | Techniques, systems and machine readable programs for magnetic resonance |
| US8660634B2 (en) * | 2012-04-23 | 2014-02-25 | The Brigham and Woman's Hospital | System and method for improved lung fourier decomposition magnetic resonance imaging |
| CN110464709A (zh) | 2012-08-10 | 2019-11-19 | 德克萨斯州大学系统董事会 | 用于治疗中风的神经保护性脂质体组合物和方法 |
| US9329246B2 (en) * | 2012-10-03 | 2016-05-03 | Bruker Biospin Ag | Method for hyperpolarization transfer in the liquid state |
| US9170215B2 (en) | 2012-10-25 | 2015-10-27 | Hexagon Metrology, Inc. | Apparatus and method of imaging a heterogeneous object |
| US20140200437A1 (en) * | 2013-01-16 | 2014-07-17 | Empire Technology Development Llc | Detection of internal gas leakage |
| AU2013200526B1 (en) * | 2013-02-01 | 2014-05-08 | Empire Technology Development Llc | Detection of internal gas leakage |
| JP6625966B2 (ja) | 2013-03-15 | 2019-12-25 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 希ガスが豊富な液体ならびにその調製及び使用の方法 |
| DE102013209832A1 (de) * | 2013-05-27 | 2014-11-27 | Siemens Aktiengesellschaft | Vorrichtung und Verfahren zur Kontrastmittelgabe bei einer Magnetresonanztomographie |
| EP3107583B1 (en) | 2014-02-21 | 2019-05-29 | Duke University | Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices |
| US10126438B2 (en) | 2014-09-19 | 2018-11-13 | University Of Virginia Patent Foundation | Systems and methods for polarized nuclear imaging and spectroscopy |
| US10692692B2 (en) * | 2015-05-27 | 2020-06-23 | Kla-Tencor Corporation | System and method for providing a clean environment in an electron-optical system |
| WO2018053256A1 (en) | 2016-09-15 | 2018-03-22 | Yuan Zheng | Systems and methods for polarized nuclear imaging and spectroscopy |
| US11944424B2 (en) | 2018-05-18 | 2024-04-02 | Duke University | Dynamic 129Xe gas exchange spectroscopy |
| CN114487959B (zh) * | 2022-01-26 | 2024-05-31 | 中国科学院精密测量科学与技术创新研究院 | 一种超低场核磁共振测量装置与方法 |
| CN115792758B (zh) * | 2022-11-30 | 2024-10-15 | 中国科学院精密测量科学与技术创新研究院 | 一种用于活体超极化氙分子探针的磁共振定量成像方法 |
| WO2025151298A1 (en) | 2024-01-10 | 2025-07-17 | Polarean, Inc. | Hyperpolarizers with a load-lock chamber for alkali metal |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4006736A (en) * | 1974-11-27 | 1977-02-08 | Medrad, Inc. | Angiographic injector |
| US4157495A (en) | 1976-08-14 | 1979-06-05 | Litton Systems, Inc. | Nuclear magnetic resonance gyro |
| DE2758855A1 (de) * | 1977-12-30 | 1979-07-12 | Litton Systems Inc | Vorrichtung zum bestimmen der magnetischen kernresonanz |
| US4450407A (en) * | 1981-10-02 | 1984-05-22 | Litton Systems, Inc. | Magnetic resonance cell and method for its fabrication |
| DE3141641A1 (de) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
| US4775522A (en) * | 1983-03-04 | 1988-10-04 | Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center | NMR compositions for indirectly detecting a dissolved gas in an animal |
| US4586511A (en) * | 1983-03-04 | 1986-05-06 | Children's Hospital Medical Center | Methods and compositions for detecting and imaging a gas in an animal by nuclear magnetic resonance |
| US4586111A (en) * | 1984-08-01 | 1986-04-29 | Sfe Technologies | Capacitor with dielectric comprising a polymer of polyacrylate polyether pre-polymer |
| US4862359A (en) * | 1984-08-31 | 1989-08-29 | Bio-Logic Systems Corporation | Topographical mapping of brain functionality from neuropsychological test results |
| US4793357A (en) * | 1986-11-24 | 1988-12-27 | Picker International, Inc. | CT blood flow mapping with xenon gas enhancement |
| US4996041A (en) * | 1988-08-19 | 1991-02-26 | Toshiyuki Arai | Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system |
| DE3828905A1 (de) * | 1988-08-23 | 1990-03-15 | Schering Ag | Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel |
| US4971258A (en) | 1988-08-26 | 1990-11-20 | Ihi Master Metal Ltd. | Method of making high-purity fine particles of reactive metals and manufacturing vessel therefor |
| US5039500A (en) | 1988-11-18 | 1991-08-13 | Kyodo Oxygen Co., Ltd. | Process for producing xenon |
| US5773024A (en) | 1989-12-22 | 1998-06-30 | Imarx Pharmaceutical Corp. | Container with multi-phase composition for use in diagnostic and therapeutic applications |
| US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
| US5046498A (en) * | 1991-01-16 | 1991-09-10 | Union Carbide Industrial Gases Technology Corporation | Magnetic resonance human medical and veterinary imaging method |
| US5186924A (en) * | 1991-01-16 | 1993-02-16 | Praxair Technology Inc. | Magnetic resonance human medical and veterinary imaging method |
| US5647361A (en) * | 1992-09-28 | 1997-07-15 | Fonar Corporation | Magnetic resonance imaging method and apparatus for guiding invasive therapy |
| US6280383B1 (en) * | 1993-03-01 | 2001-08-28 | Fonar Corporation | Magnetic resonance imaging |
| US5357959A (en) * | 1993-04-16 | 1994-10-25 | Praxair Technology, Inc. | Altered dipole moment magnetic resonance imaging method |
| US5433196A (en) * | 1993-06-02 | 1995-07-18 | The Board Of Trustees Of The University Of Illinois | Oxygen-17 NMR spectroscopy and imaging in the human |
| US5545396A (en) * | 1994-04-08 | 1996-08-13 | The Research Foundation Of State University Of New York | Magnetic resonance imaging using hyperpolarized noble gases |
| FR2744932B1 (fr) * | 1996-02-16 | 1998-04-30 | Centre Nat Rech Scient | Installation et procede pour la production d'helium-3 polarise en phase vapeur, en particulier pour l'imagerie par rmn |
| US5809801A (en) * | 1996-03-29 | 1998-09-22 | The Trustees Of Princeton University | Cryogenic accumulator for spin-polarized xenon-129 |
| FI982069A7 (fi) * | 1996-03-29 | 1998-11-10 | Lawrence Berkeley Nat Laboratory | NMR:n ja MRI:n tehostaminen hyperpolaroitujen jalokaasujen läsnä olles sa |
| DE19619471C1 (de) * | 1996-05-14 | 1997-10-16 | Siemens Ag | Kernspintomographiegerät mit Vorpolarisation |
| EP0951650B1 (en) * | 1997-01-08 | 2003-12-10 | Amersham Health AS | Method of magnetic resonance imaging |
-
1994
- 1994-04-08 US US08/225,243 patent/US5545396A/en not_active Expired - Lifetime
-
1995
- 1995-04-04 WO PCT/US1995/004175 patent/WO1995027438A1/en not_active Ceased
- 1995-04-04 CA CA002183740A patent/CA2183740C/en not_active Expired - Fee Related
- 1995-04-04 EP EP95916198A patent/EP0754009B1/en not_active Expired - Lifetime
- 1995-04-04 EP EP07020546A patent/EP1873544A3/en not_active Withdrawn
- 1995-04-04 DE DE69536022T patent/DE69536022D1/de not_active Expired - Lifetime
- 1995-04-04 AT AT95916198T patent/ATE449615T1/de active
- 1995-04-04 JP JP52641295A patent/JP3645569B2/ja not_active Expired - Fee Related
- 1995-04-04 AU AU22787/95A patent/AU709515B2/en not_active Ceased
- 1995-06-07 US US08/485,356 patent/US5789921A/en not_active Expired - Lifetime
-
1996
- 1996-06-17 US US08/666,871 patent/US5785953A/en not_active Expired - Lifetime
-
1998
- 1998-03-18 US US09/040,788 patent/US6241966B1/en not_active Expired - Fee Related
-
2000
- 2000-12-19 US US09/741,292 patent/US6593144B2/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002511329A (ja) * | 1998-04-09 | 2002-04-16 | メディ−フィジックス・インコーポレイテッド | 肺からの酸素吸収における領域変化のmri検出のための過分極ガスの使用 |
| JP2002534683A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | Nmr分光法 |
| JP2002534687A (ja) * | 1998-12-30 | 2002-10-15 | アメルシャム・パブリック・リミテッド・カンパニー | 過分極を使用したnmr分光学アッセイ |
| JP2018512384A (ja) * | 2015-02-20 | 2018-05-17 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | 溶解ガス発生流体を有するコントラスト造影剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0754009B1 (en) | 2009-11-25 |
| AU709515B2 (en) | 1999-09-02 |
| DE69536022D1 (de) | 2010-01-07 |
| JP3645569B2 (ja) | 2005-05-11 |
| EP1873544A3 (en) | 2008-06-04 |
| CA2183740C (en) | 2002-05-28 |
| US6241966B1 (en) | 2001-06-05 |
| EP0754009A4 (en) | 1999-10-20 |
| US5789921A (en) | 1998-08-04 |
| EP1873544A2 (en) | 2008-01-02 |
| US5785953A (en) | 1998-07-28 |
| CA2183740A1 (en) | 1995-10-19 |
| US5545396A (en) | 1996-08-13 |
| US20010000726A1 (en) | 2001-05-03 |
| ATE449615T1 (de) | 2009-12-15 |
| WO1995027438A1 (en) | 1995-10-19 |
| US6593144B2 (en) | 2003-07-15 |
| EP0754009A1 (en) | 1997-01-22 |
| AU2278795A (en) | 1995-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3645569B2 (ja) | 過分極した貴ガスを利用した磁気共鳴映像化 | |
| Möller et al. | MRI of the lungs using hyperpolarized noble gases | |
| US7385395B2 (en) | Apparatus for preparing a solution of a hyperpolarized noble gas for NMR and MRI analysis | |
| Månsson et al. | 13C imaging—a new diagnostic platform | |
| Bachert et al. | Nuclear magnetic resonance imaging of airways in humans with use of hyperpolarized 3He | |
| US5248498A (en) | Fullerene compositions for magnetic resonance spectroscopy and imaging | |
| Driehuys et al. | Pulmonary perfusion and xenon gas exchange in rats: MR imaging with intravenous injection of hyperpolarized 129Xe | |
| US6123919A (en) | Magnetic resonance imaging using hyperpolarized noble gases | |
| Ruppert | Biomedical imaging with hyperpolarized noble gases | |
| Mills et al. | Functional magnetic resonance imaging of the lung | |
| Six et al. | Pulmonary MRI contrast using Surface Quadrupolar Relaxation (SQUARE) of hyperpolarized 83Kr | |
| Goodson | Using injectable carriers of laser‐polarized noble gases for enhancing NMR and MRI | |
| Guenther et al. | Functional MR imaging of pulmonary ventilation using hyperpolarized noble gases | |
| Mosbah et al. | Aerosols and gaseous contrast agents for magnetic resonance imaging of the lung | |
| Aime et al. | Agents for polarization enhancement in MRI | |
| Wolber et al. | Intravascular delivery of hyperpolarized129Xenon for in vivo MRI | |
| Grigor’ev et al. | Production and applications of spin-polarized isotopes of noble gases | |
| Pourfathi | Metabolic imaging of acute lung injury using hyperpolarzied 13C magnetic resonance imaging | |
| Lesbats | Hyperpolarized noble gases as biomarkers for pulmonary pathology | |
| KRYPTON | Stupic, John E. Repine, and Thomas Meersmann,“Hyperpolarized" Kr MRI of Lungs" to | |
| van Beek et al. | Helium MR Imaging | |
| van Beek et al. | Noble Gas Ventilation Imaging Using^ 3He and^ 1^ 2^ 9Xe: An Introduction | |
| Mada | Application of hyperpolarised Helium-3 in lung functional magnetic resonance imaging | |
| White | Volume estimation from three-dimensional hyperpolarized 129Xe magnetic resonance images | |
| Månsson | Hyperpolarized Nuclei for NMR Imaging and Spectroscopy–Methodology and model studies of lung and vascular function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040330 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041008 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050111 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050204 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090210 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090210 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100210 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100210 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110210 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120210 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130210 Year of fee payment: 8 |
|
| LAPS | Cancellation because of no payment of annual fees |